Michael Johnson

Mr Johnson has been responsible for the development of Rhinomed's nasal technology platform and has led Rhinomed to being one of the world's leading developers of wearable nasal medical technology. The company has successfully commercialised six products including solutions in the global sleep, snoring, and respiratory markets. More recently, and in response to the global pandemic, Mr Johnson has led the development of the revolutionary new Rhinoswab and Rhinoswab Junior - the world's first nasal swab designed specifically for children. Over the course of his career, he has worked for large multinationals through to start-ups and across sectors - from Life Sciences, Cleantech, Financial Services and the Media and Communication industries. Mr Johnson is the lead author of over 50 patents and has co-authored research in the Journal of Clinical Psychiatry on Sleep and Suicide. Mr Johnson is a non-executive director of the US based Foundation for Airway Healt.

Company and Roles

Company
Title
Tenure
Since
RNO
Rhinomed Limited
  • Chief Executive Officer
  • Executive Director
11yrsFeb 2013

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
RNO
Rhinomed Limited
02/02/24511,7711,336,84625,380,913N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
RNO
Rhinomed Limited
02/02/24
Buy
750,000$0.040$30,000Participation in share purchase plan
RNO
Rhinomed Limited
02/02/24
Buy
130,165$0.026$3,384Participation in share purchase plan
RNO
Rhinomed Limited
29/11/23
Expiry
5,000,000$0.041$205,000Options expired
RNO
Rhinomed Limited
03/05/23
Buy
55,555$0.072$4,015On-market trade
RNO
Rhinomed Limited
06/05/22
Issued
51,136$0.190$9,716Rights issue